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ENGLISH SUMMARY 
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and 
treatable disease characterized by persistent respiratory symptoms and airflow 
limitation. The disease usually arises due to airway and/or alveolar abnormalities that 
are often caused by significant exposure to noxious particles or gases. COPD is a 
major socio-economic burden that is associated with significant morbidity and 
mortality worldwide. The burden of the disease is mainly due to exacerbations, which 
are defined as acute worsenings of respiratory symptoms that result in additional 
therapy. COPD exacerbations have a negative impact on health status, rate of 
hospitalization and readmission, and disease progression. Although exacerbations are 
both treatable and preventable, a substantial portion of unreported exacerbations is a 
challenge in the management of COPD. Telemonitoring of patients with COPD and 
the application of predictive analytics have been proposed as a potential solution, and 
several previous studies have attempted to develop predictive models for upcoming 
exacerbations. However, no previously reported studies have achieved a level of 
clinical relevance for implementation in the telemonitoring of patients with COPD. 
Although previous exacerbations are clinically recognized as a predictor of future 
exacerbations, no previous studies have investigated this potential. 
The objective of this thesis was to improve methods for assessing predictive models 
and to explore the potential of including information on previous exacerbations in the 
prediction of upcoming exacerbations in patients with COPD. The thesis was based 
on four studies presented in four individual papers. Study I and study IV explored the 
potential of including information on previous exacerbations, whereas study II and 
study III involved methodological research for assessing predictive models leading up 
to study IV. Study I investigated whether patient and population exacerbation 
incidence contain predictive information of upcoming exacerbations. This study was 
based on home measurements of physiological parameters in a large cohort of 
telemonitored patients with COPD, but the study was limited by the frequency of the 
submitted measurements. To determine whether the predictive models could be 
improved with a higher frequency of measurements, a smaller cohort of telemonitored 
patients with more frequent measurements was investigated in studies II-IV. A 
challenge when developing predictive models in a smaller cohort is over-fitting. 
Therefore, study II investigated whether double cross-validation with feature selection 
was a more robust validation method than conventional cross-validation for 
preventing over-fitting and ensuring generalizable test results. Study III 
systematically compared nine classification algorithms to assess the sensitivity to the 
choice of classification algorithm for predictive models for COPD exacerbations. 
VI 
Study IV combined the work of studies I-III and investigated whether a two-layer 
probabilistic model could increase classification rates compared to conventional 
models for predicting COPD exacerbations. 
The conducted studies revealed that the population exacerbation incidence holds 
predictive information of upcoming exacerbations for telemonitored patients. Double 
cross-validation with feature selection proved to be a more robust validation method 
than conventional cross-validation for predicting COPD exacerbations in a small 
imbalanced data set. Prediction models for COPD exacerbations are highly sensitive 
to the choice of classification algorithm, and several classification algorithms should 
therefore be compared systematically when developing predictive models. Finally, a 
two-layer probabilistic model can significantly increase the classification rates to a 
level of clinical relevance compared to a conventional one-layer model for predicting 
COPD exacerbations. In conclusion, double cross-validation should be used to 
develop and compare models based on several classification algorithms, and there is 
great potential in including information on previous exacerbations in the prediction of 
upcoming exacerbations in patients with COPD. This could allow for clinical 
implementation and potentially reduce the morbidity, mortality, and socio-economic 
burden related to COPD. 
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DANSK RESUME 
Kronisk obstruktiv lungesygdom (KOL) er en almindelig, forebyggelig og 
behandlelig sygdom, der er kendetegnet ved vedvarende luftvejssymptomer og  
luftvejsobstruktion. Sygdommen skyldes normalt luftvejs- og/eller alveolære 
abnormaliteter, som oftest forårsages af en betydelig eksponering for skadelige 
partikler eller gasser. KOL er en stor socioøkonomisk burde, som er associeret med 
betydelig sygelighed og dødelighed verden over. Sygdomsbyrden skyldes primært 
exacerbationer, der defineres som akutte forværringer af luftvejssymptomer, som 
kræver yderligere behandling. KOL exacerbationer har en negativ påvirkning på 
sundhedsstatus, indlæggelses- og genindlæggelsesrate og sygdomsprognose. Selvom 
exacerbationer både kan behandles og forebygges, er en betydelig mængde 
urapporterede exacerbationer en udfordring i håndteringen af KOL. Telemonitorering 
af patienter med KOL og anvendelsen af prædiktive analyser er blevet foreslået som 
en potentiel løsning, hvor flere tidligere studier har forsøgt at udvikle prædiktive 
modeller for kommende exacerbationer. Imidlertid har ingen tidligere rapporterede 
studier opnået et niveau af klinisk relevans til at kunne implementeres i 
telemonitoreringen af patienter med KOL. Selvom tidligere exacerbationer er en 
klinisk anerkendt prædiktor for kommende exacerbationer, har ingen tidligere studier 
undersøgt dette potentiale.   
Formålet med denne afhandling var at forbedre metoder til at vurdere prædiktive 
modeller og at undersøge potentialet i at inkludere information om tidligere 
exacerbationer i prædiktionen af kommende exacerbationer hos patienter med KOL. 
Afhandlingen var baseret på fire studier, som er præsenteret i fire individuelle artikler. 
Studie I og studie IV undersøgte potentialet i at inkludere information om tidligere 
exacerbationer, mens studie II og studie III omhandlede metodisk forskning, der ledte 
frem til studie IV. Studie I undersøgte, om patient- og populationsincidensen af 
exacerbationer indeholder prædiktiv information om kommende exacerbationer. 
Dette studie var baseret på hjemmemålinger af fysiologiske parametre i en stor 
kohorte af telemonitorerede patienter med KOL, men studiet var begrænset af 
frekvensen af de indsendte målinger. En mindre kohorte med hyppigere målinger blev 
undersøgt i studierne II-IV med henblik på at afgøre, om de prædiktivere modeller 
kunne forbedres med en højere målefrekvens. Over-fitting er en udfordring, når der 
udvikles prædiktive modeller i en mindre kohorte. Derfor undersøgte studie II, om 
dobbelt krydsvalidering med valg af prædiktorer er en mere robust valideringsmetode 
end konventionel krydsvalidering til at forhindre over-fitting og sikre generaliserbare 
testresultater. Studie III foretog en systematisk sammenligning af ni 
klassifikationsalgoritmer for at vurdere sensitiviten over for valg af 
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klassifikationsalgoritme for prædiktive modeller for exacerbationer af KOL. Studie 
IV kombinerede studierne I-III og undersøgte, om en to-lags probabilistisk model 
kunne øge klassifikationsraterne, sammenlignet med konventionelle modeller, til 
prædiktion af exacerbationer af KOL.  
De gennemførte studier viste, at populationsincidencen af exacerbationer indeholder 
prædiktiv information om kommende exacerbationer hos telemonitorerede patienter. 
Dobbelt krydsvalidering med valg af prædiktorer blev anset som en mere robust 
valideringsmetode end konventionel krydsvalidering for prædiktion af KOL 
exacerbationer i et lille ubalanceret data sæt. Prædiktive modeller er yderst sensitive 
over for valg af klassifikationsalgoritme, og derfor bør flere klassifikationsalgoritmer 
sammenlignes systematisk under udviklingen af en prædiktiv model. Endelig kan en 
to-lags probabilistisk model øge klassifikationsraterne signifikant til et niveau af 
klinisk relevans sammenlignet med en konventionel et-lags model for prædiktion af 
exacerbationer af KOL. Som konklusion bør dobbelt krydsvalidering anvendes til at 
udvikle og sammenligne modeller baseret på flere klassifikationalgoritmer, og der er 
et stort potentiale i at inkludere information om tidligere exacerbationer i 
prædiktionen af kommende exacerbationer hos patienter med KOL. Dette kunne 
muliggøre en klinisk implementering og potentielt reducere sygeligheden, 
dødeligheden og den socioøkonomiske byrde relateret til KOL. 
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PREFACE 
This PhD thesis has been submitted to the Doctoral School in Medicine, Biomedical 
Science and Technology at Aalborg University in fulfilment of the requirements for 
the PhD degree. The thesis was based on the scientific work that was accomplished 
during the PhD study from August 2016 to November 2019 at the Department of 
Health Science and Technology. The PhD study was supervised by Professor Ole 
Hejlesen and co-supervised by Postdoc Simon Lebech Cichosz at Aalborg 
University. 
The thesis is based on four studies that were conducted during the PhD study, which 
are presented in four different papers. The thesis additionally includes a background 
that presents the research area, which leads to the objective of the thesis. The four 
studies are then presented along with their individual contributions. The thesis ends 
in a discussion of the included studies, the significance of the conducted research, 
and future perspectives along with a conclusion that summarizes the main findings 
of the thesis. 
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CHAPTER 1. INTRODUCTION 
The following chapter presents the rationale for this PhD study. 
Chronic obstructive pulmonary disease (COPD) is a major public health problem that 
is associated with a substantial impact on morbidity, mortality, and socio-economic 
costs worldwide. The burden related to COPD is primarily attributable to 
exacerbations, which are acute worsenings of respiratory symptoms that result in 
additional therapy. Although exacerbations are both treatable and preventable, 
unreported exacerbations are a challenge in the management of COPD. 
Telemonitoring and the application of predictive analytics have been proposed as a 
potential solution, but there is an urgent need to develop better predictive models for 
exacerbations. This thesis contributes to the field of COPD research by exploring a 
new potential to improve the state-of-the-art in the use of predictive analytics for 
telemonitoring of patients with COPD. The conducted research could potentially lead 
to clinical implementation and assist patients and healthcare personnel in better 
managing COPD. 
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CHAPTER 2. BACKGROUND 
This chapter will describe the human respiratory system and the development of 
COPD. Subsequently, the focus will shift to exacerbations when describing the global 
burden of the disease and the challenges in the management thereof. Finally, the 
chapter presents the state-of-the-art in the management of the disease with predictive 
analytics and what has yet to be explored. 
2.1 THE HUMAN RESPIRATORY SYSTEM 
The human respiratory system is responsible for taking in oxygen and disposing 
carbon dioxide within the lungs. The upper respiratory system consists of the nasal 
cavity, paranasal sinuses, pharynx (throat), and larynx (voice box) [1]. These 
pathways filter and humidify the incoming air to protect the more delicate surfaces of 
the lower respiratory system [2]. In the lower respiratory system, the air continues 
through the trachea (windpipe), which bifurcates into the left and right primary 
bronchi [1]. The right primary bronchus supplies the right lung, and the left primary 
bronchus supplies the left lung (Figure 1). 
Figure 1. Anatomy of the respiratory system. 
The primary bronchi then branch to form secondary and tertiary bronchi. The trachea 
and main bronchi contain C-shaped rings of cartilage, which serve to support and 
protect the airways [2]. Each bronchus further divides repeatedly, where each 
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generation approximately doubles in number, the cartilage progressively decreases, 
and the amount of smooth muscle tissue increases. Bronchioles begin at 
approximately generation 12, in which cartilage is absent and the airways are 
embedded in the elastic lung tissue. Terminal bronchioles (generation 16) lead to 
respiratory bronchioles, which are the first generation to have alveoli in their walls 
[1]. Alveoli are air-filled pockets where gas exchange takes place between the lungs 
and blood [2]. Respiratory bronchioles lead to alveolar ducts and alveolar sacs 
(generation 23), whose walls are entirely composed of alveoli [1]. A thin epithelial 
membrane between the alveoli and surrounding capillaries, generally narrower than 1 
µm, ensures a quick and efficient gas exchange. To meet the metabolic requirements 
of the body, the lungs must provide a large surface area for gas exchange. Each lung 
contains approximately 150 million alveoli, which are associated with an extensive 
network of alveolar capillaries. The surface area involved in gas exchange has been 
estimated to range from 70 m2 to 140 m2 [2]. During inhalation, skeletal muscles cause 
an elevation of the ribcage along with a contraction and downward motion of the 
diaphragm. The increased thoracic volume causes a decrease in the intrapleural and 
alveolar pressure that draws air into the lungs [1]. 
The airways from the trachea to the respiratory bronchioles are lined with ciliated 
columnar or cuboidal epithelial cells. Mucus cells and mucus glands within the 
epithelium secrete a sticky mucus that lines the exposed surfaces to trap debris or 
pathogens that have entered the airways. Synchronous movement of the cilia moves 
the mucus from the lungs towards the pharynx, from where the mucus is swallowed 
and exposed to the acids and enzymes of the stomach [2]. 
2.1.1 GAS EXCHANGE 
Oxygen and carbon dioxide are exchanged by diffusion though the alveolar-capillary 
membrane. This gas exchange is a response to concentration gradients from differing 
partial pressures within the alveolar air and the blood [1]. Inhaled air is a mixture of 
gases, where nitrogen accounts for 78.6%, and therefore the vast majority of 
molecules, while oxygen makes up approximately 20.9% percent of the air. The 
remaining 0.5% of molecules mostly consist of water, with carbon dioxide 
contributing 0.04%. The combined effect of the molecules in the air results in an 
atmospheric pressure of 760 mmHg. The partial pressure of oxygen in the dry inhaled 
air is therefore 159 mmHg, while the partial pressure of carbon dioxide is 0.3 mmHg. 
As the inhaled air is humidified in the upper respiratory system, the partial pressure 
of oxygen in the alveoli is 100 mmHg. Upon reaching the alveoli, the inhaled air also 
mixes with air remaining from the previous exhalation, resulting in a partial pressure 
of 40 mmHg for carbon dioxide [2]. 
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Deoxygenated blood reaches the alveolar capillaries from the heart though the left and 
right pulmonary arteries. The blood contains a lower partial pressure of 40 mmHg for 
oxygen and a higher partial pressure of 45 mmHg for carbon dioxide compared to the 
alveolar air. This results in a pressure gradient that forces oxygen from the alveoli into 
the blood and forces carbon dioxide from the blood into the alveoli. The blood then 
reaches equilibrium with the alveolar air at a partial pressure of 100 mmHg for oxygen 
and 40 mmHg for carbon dioxide. The oxygenated blood then departs from the alveoli 
and returns to the heart through the pulmonary veins before it is pumped into the 
systemic circuit to supply the body with oxygen [2]. An important note is that the 
body needs more oxygen and generates more carbon dioxide than what can be 
dissolved in the blood. Red blood cells therefore play an important role in binding 
molecules dissolved in the blood, which causes a continuous diffusion of gasses [1]. 
Only 1.5% of the oxygen molecules are dissolved in the blood leaving the alveoli, 
whereas the rest are bound to haemoglobin within the red blood cells. Carbon dioxide 
is generated in peripheral tissues and transported either as carbonic acid (~70%), 
bound to haemoglobin (~23%), or dissolved in the blood (~7%). These reactions are 
both temporary and reversible, as red blood cells remove excess molecules when the 
concentrations in the blood are high and release their stored reserve when 
concentrations are low [2]. 
2.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
COPD is defined as a common, preventable and treatable disease that is characterized 
by persistent airflow limitation that is due to airway and/or alveolar abnormalities 
usually caused by significant exposure to noxious particles or gases [3]. Long-term 
exposure causes chronic inflammation in the airways, usually referred to as chronic 
bronchitis, and causes both small airway diseases and parenchymal destruction. 
Chronic bronchitis causes a narrowing of the small airways due to mucosal 
inflammation and secretion and decreases the elasticity of the lungs (Figure 2) [1]. 
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Figure 2. Airway and alveolar abnormalities in COPD. 
The repeated injury and repair of the air wall itself may also lead to an excessive 
production of muscle and fibrous tissue [4]. This restricts the airflow to the alveoli 
and diminishes the ability of the small airways to remain open during exhalation. The 
latter results in trapping of air with a low partial pressure of oxygen and a high partial 
pressure of carbon dioxide. The trapped air does not contribute to gas exchange in the 
alveoli, while deoxygenated blood still perfuses through the pulmonary capillaries. 
Chronic inflammation also leads to a loss of alveolar attachments and a destruction of 
the alveoli [3]. This is commonly referred to as emphysema and causes adjacent 
alveoli to merge and form larger air sacs (Figure 2). This greatly limits the surface 
area involved in gas exchange and the diffusion of oxygen, so the individual becomes 
short of breath [2]. Noxious exposure also causes a destruction of ciliary function. 
This leads to chronic cough and increased sputum production as the lungs can no 
longer remove mucus with associated debris or pathogens. This causes further 
narrowing, inflammation, and irritation of the airways. Dyspnoea (shortness of 
breath), chronic cough, and increased sputum production are therefore the most 
characteristic symptoms of COPD [3]. 
2.2.1 THE BURDEN OF COPD 
COPD is a complex and heterogeneous disease that is responsible for substantial and 
increasing morbidity, mortality and healthcare expenditures worldwide [5]. It has 
been estimated that 384 million people have COPD, with a global prevalence of 11.7% 
[6]. COPD has climbed from the fourth leading cause of death in 1990 to the third 
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leading cause of death in 2010 [7]. Each year, COPD is responsible for 3 million 
deaths, representing nearly 6% of all deaths globally [8]. The burden of the disease is 
projected to increase further over the coming decades due to continued exposure to 
COPD risk factors in developing countries and ageing populations in high-income 
countries [9]. It is estimated that as many as 4.5 million deaths from COPD will occur 
in 2030 [10]. 
The direct cost of respiratory diseases in the European Union is €55 billion, where 
COPD accounts for the majority of the costs at €23.3 billion. If the indirect costs and 
monetized value of disability-adjusted life years are included, the total cost of COPD 
is estimated at €141 billion, equal to 37% of the total costs of respiratory diseases 
[11]. The global burden of the disease is primarily attributable to COPD 
exacerbations, and there is a striking relationship between disease progression and 
healthcare cost [3]. 
2.2.2 RISK FACTORS FOR COPD 
COPD develops from a complex interaction between environmental exposure and 
genetics [3]. Cigarette smoke is the most common risk factor for COPD, and smokers 
are associated with a higher prevalence of respiratory symptoms, lung function 
abnormalities, a greater annual rate of decline in lung function, and a greater COPD 
mortality rate compared to non-smokers [12,13]. Other types of tobacco use, such as 
pipes, cigars, and water pipes, and marijuana use are also risk factors for COPD [14–
16]. Passive exposure to cigarette smoke may also contribute to respiratory symptoms 
and COPD [17]. Occupational exposure to organic and inorganic dusts, chemical 
agents, and fumes are also often over-looked risk factors for COPD even in non-
smokers [18–20]. 
Age is also often presented as a risk factor for COPD, as COPD predominantly 
develops after the age of 40 [21]. However, it is not clear whether age reflects the sum 
of exposure throughout life or whether ageing of the lungs appears similar to the 
structural changes associated with COPD [22]. Previous studies have often reported a 
greater COPD prevalence and mortality among men, but recent data from developed 
countries suggest that the prevalence of COPD is now almost equal between men and 
women [23]. Some studies have even suggested that the effects of tobacco smoke lead 
to a more severe disease in women compared to men for an equal quantity of smoked 
cigarettes [24–26]. 
Asthma might also be a risk factor for developing COPD, as adults with asthma have 
been found to have a 12-fold higher risk of developing COPD over time compared to 
adults without asthma after adjusting for smoking [27]. Another study reported that 
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approximately 20% of subjects with childhood asthma later developed persistent 
airflow limitation and decreased diffusion capacity [28]. Lung growth and 
development as well as respiratory infections in early childhood also have the 
potential to increase the risk of COPD developing later in life [29–31]. A severe 
hereditary alpha-1-antitrypsin deficiency is also among the best documented genetic 
risk factors for COPD [3,32]. Furthermore, there appears to be a significant familial 
risk of airflow limitation that has been observed in smokers who have siblings with 
severe COPD [33]. 
2.2.3 COPD DIAGNOSIS AND ASSESSMENT 
COPD should be considered in any patient with shortness of breath, chronic cough, 
and sputum production with a history of risk factors. In a clinical context, a post-
bronchodilator spirometry is required to diagnose COPD, where a ratio between the 
forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) of less 
than 70% confirms the presence of persistent airflow limitation [3]. A reduction in the 
FEV1/FVC ratio is correlated with the extent of inflammation, mucus, and fibrosis of 
the airways [34]. Thus, COPD is diagnosed in a patient with persistent airflow 
limitation who presents with appropriate symptoms with significant exposure to 
noxious stimuli [3]. 
Assessment of COPD involves determining the level of airflow limitation, the impact 
on health status, and the risk of future events (exacerbations, hospital admissions or 
death) to guide therapy [3]. The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) classification can be used to categorize the level of airflow 
limitation, from 1 (mild) to 4 (very severe), based on the predicted FEV1 percentage 
compared to an average healthy person of the same age, race, height, and gender [3]. 
The most widely used measures for assessing symptoms are the Modified British 
Medical Research Council (mMRC) dyspnoea scale, from 0 to 4, for assessing 
breathlessness [35] and the 8-item COPD Assessment Test (CAT) to measure health 
status impairment in COPD using a score from 0 to 40 [36]. It is also important to 
determine the history of exacerbations to assess the risk of future exacerbations [3,37]. 
2.2.4 COPD EXACERBATIONS 
COPD is characterized by exacerbations, which are defined as an acute worsening of 
respiratory symptoms that results in additional therapy [3,38,39]. Patients with COPD 
with moderate airflow limitation may experience exacerbations that require treatment 
with antibiotics and/or systemic corticosteroids, but the risk of exacerbations is 
significantly higher for severe and very severe patients [3]. Exacerbations are 
important in managing COPD, as they have a negative impact on health status, rate of 
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hospitalization and readmission, and disease progression [38,40,41]. Exacerbations 
are complex and usually associated with an increase in airway inflammation, mucus 
production, and gas trapping. These changes cause increased dyspnoea, which is the 
key symptom of an exacerbation. Exacerbations are classified as mild (treated with 
short-acting bronchodilators), moderate (treated with short-acting bronchodilators 
plus antibiotics and/or oral corticosteroids), and severe (requiring hospitalization or 
an emergency room visit). Severe exacerbations may result in acute respiratory failure 
[3]. 
Exacerbations are mainly initiated by respiratory viral infections, while bacterial 
infections and environmental exposure (e.g., pollutants or temperature) may also 
initiate and/or amplify such events [42]. Lower respiratory tract viral infections may 
directly damage the airways in patients with COPD, resulting in a loss of the ciliated 
epithelium with increased inflammation and mucus production [43]. In addition to a 
further narrowing of the airways, the alterations may also promote a secondary 
bacterial infection, causing more inflammation and damage [44]. Exacerbations 
associated with viral infections, e.g., the human rhinovirus as commonly seen during 
winter [42], are often more severe, longer lasting, and cause more hospitalizations [3]. 
Symptoms during an exacerbation usually lasts 7 to 10 days, with systemic 
inflammation reaching baseline levels after 14 days, although severe exacerbations 
may last longer [45,46]. 
2.2.5 MANAGEMENT OF COPD 
Once COPD is diagnosed, effective management should aim towards improving the 
patient’s health status while reducing the current symptoms and the future risk of 
exacerbations. The identification and reduction of noxious exposure are important for 
treating and preventing the development of COPD [3]. Cigarette smoking is the most 
prevalent risk factor, and smoking cessation should be highly encouraged for all 
patients with COPD who continue to smoke [47]. Influenza vaccination can reduce 
lower respiratory tract infections [48] and mortality in patients with COPD [49]. This 
vaccination is especially important in elderly patients [50]. The pneumococcal vaccine 
can also provide significant protection against community-acquired pneumonia and 
reduce the likelihood of a COPD exacerbation [51]. Pharmacological treatment of 
COPD can reduce symptoms and the frequency of exacerbations while increasing the 
health-related quality of life and exercise tolerance for patients with COPD [52]. The 
treatment primarily involves the use of bronchodilators (relaxes airway smooth 
muscle to open up the airways), antibiotics (reduce exacerbation rate), and inhaled 
corticosteroids (reduce airway inflammation) [3]. In very severe cases of COPD with 
chronic respiratory failure, oxygen therapy has been shown to increase survival [53]. 
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Additionally, COPD often coexists with other diseases (comorbidities), and it has 
been increasingly recognized that COPD is part of a systemic disease [54,55]. 
Comorbidities of COPD include cardiovascular diseases [56], lung cancer [57], 
diabetes [58], osteoporosis [59], loss of skeletal muscle [60], renal failure [61], 
anxiety and depression [62], among others [63,64], that all have negative effects on 
the disease prognosis. Comorbidities may arise from sharing risk factors with COPD, 
e.g., smoking, while some diseases may increase the risk of others [3]. Comorbidities 
of COPD have also been shown to affect exacerbations [65]. For instance, heart failure 
is frequent and often unrecognized in patients hospitalized for COPD exacerbations 
[66]. COPD is therefore increasingly recognized as the pulmonary component of 
multimorbidity, which should be taken into consideration when managing COPD [3]. 
COPD exacerbations are especially important to treat, with the goal of minimizing the 
negative impact of the current exacerbation and preventing subsequent exacerbations 
[3]. More than 80% of exacerbations may be managed outside the hospital with 
bronchodilators, corticosteroids, and antibiotics [45,67,68]. Exacerbations with severe 
symptoms of acute respiratory failure also require ventilator support and 
hospitalization [3]. The in-hospital mortality for patients admitted for COPD 
exacerbations with hypercapnic respiratory failure has been reported to be 11%, with 
a 33% mortality after 180 days and a 49% mortality after 2 years [69]. Early treatment 
has been associated with faster recovery, and patients with a high proportion of 
reported exacerbations have better health-related quality of life and a decreased risk 
of emergency hospitalization [70]. However, patients with COPD generally have a 
poor understanding of their disease and symptoms, thus delaying presentation or 
failing to seek treatment during exacerbation [40]. It has been estimated that 
approximately 40% to 70% of exacerbations are not reported to healthcare 
professionals [40,70,71]. This is of great concern, as untreated exacerbations are 
associated with a significant worsening of respiratory symptoms and health-related 
quality of life, a longer recovery time from the exacerbation and a faster deterioration 
in lung function [72,73]. Therefore, there is an urgent demand for developing tools 
that emphasize the early identification of COPD exacerbations [74]. Telemonitoring 
of patients with COPD and the application of predictive analytics have been proposed 
as a potential solution to predict exacerbations prior to onset. 
2.3 TELEMONITORING FOR MANAGING COPD 
Telemonitoring is an application of telecommunication technology that allows 
communication and remotely collected clinical data to be exchanged between the 
patient’s home and the healthcare provider on a regular basis. Telemonitored data can 
involve physiological measurements (e.g., spirometry, blood pressure, oxygen 
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saturation) and/or respiratory symptom questionnaires (e.g., ‘more cough than usual’, 
‘sputum purulence’, etc.). Telemonitoring has the potential to improve the quality of 
life in patients with COPD while reducing exacerbations and hospital admissions 
through personalized counselling and feedback from the healthcare provider [75]. 
Although telemonitoring may have a positive effect on empowerment and quality of 
life among patients with COPD, the effect on exacerbations and hospitalizations is 
unconvincing [76–82]. However, this emerging data-rich environment encourages the 
use of predictive analytics to assist the management of COPD though predicting 
exacerbations prior to onset [83]. This could facilitate an early and preventive 
treatment of exacerbations and presumably lead to better patient outcomes and a 
decreased risk of hospitalization [70]. 
2.3.1 PREDICTIVE ANALYTICS IN CONCEPT 
Within predictive analytics, statistical or machine learning methods are used to model 
an outcome based on a set of informative predictors [84]. A fictional example of a 
binary outcome could be to predict whether a patient with COPD will encounter an 
exacerbation in the upcoming week. For this prediction example, the model could be 
based on measurements of blood pressure and oxygen saturation from the past week. 
The model would rely on patterns in the data set to make decisions or predictions of 
the outcome [84]. Generally, the development of a predictive model starts with 
acquiring a representative data set including a desired outcome and a series of 
variables. Pre-processing follows to condition the data set with the extraction of 
potential predictors. Subsequently, the task is to identify the subset of predictors that 
is most informative of the outcome and then select an appropriate classification 
algorithm to base the model upon. One can think of a classification algorithm as a 
function approximation problem that maps an input of predictors to the corresponding 
outcome. Finally, the model should be tested on previously unseen data, where the 
model is only given the predictors as input. The true performance of the model is then 
determined by comparing the model-predicted outcomes to the true outcomes [85]. 
For a binary outcome, there are four possibilities when comparing the model-
predicted outcomes to the true outcomes (Table 1). There are two correct cases in 
which the model correctly predicts either the positive outcome (e.g., COPD 
exacerbation in the upcoming week encoded as a ‘1’) or the negative outcome (no 
COPD exacerbation encoded as a ‘0’). These two cases are referred to as true positive 
and true negative, respectively. If the model-predicted outcome is not in accordance 
with the true outcome, there can either be a false positive (wrongly predicted COPD 
exacerbation) or a false negative (wrongly predicted absence of COPD exacerbation). 
The performance of a model is often expressed using several statistical measures, 
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often referred to as classification rates. These include sensitivity, specificity, positive 
predictive value, negative predictive value, and accuracy, which are all extracted 
based on the ratios among true positives, true negatives, false positives, and false 
negatives (Table 1) [86]. 
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(TP) 
False positive 
(FP) 
Positive predictive 
value: 
TP
TP + FP
 
0 
False negative 
(FN) 
True negative 
(TN) 
Negative predictive 
value: 
TN
TN + FN
 
  Sensitivity: 
TP
TP + FN
 
Specificity: 
TN
TN + FP
 
Accuracy: 
TP + TN
TP + FP + FN + TN
 
 
Table 1. Prediction outcome and classification rates of model performance. Inspired 
from [86]. 
The classification rates presented above are considered threshold-specific and are 
therefore often a poor metric of the general performance of a model. A model will 
often output the probability of the positive outcome (COPD exacerbations in the 
upcoming week) instead of the outcome itself. A threshold will then determine the 
probability at or above which the positive class will be predicted based on the model. 
A low threshold would, for example, often result in a model with high sensitivity and 
low specificity due to many true positives at the cost of many false positives [86]. 
The receiver operating characteristic (ROC) curve is a technique for visualizing the 
general performance of a model (Figure 3). A ROC curve is generated by varying the 
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probability threshold from 0 to 1 while displaying the trade-off between the true 
positive rate (sensitivity) and the false positive rate (1-specificity) [86]. 
 
Figure 3. Examples of receiver operating characteristic curves for two models and 
their corresponding area under the curve values. 
A common method to quantify the general performance of a model is the area under 
the ROC curve (AUC). The AUC ranges from 0 to 1, where an AUC of 1 corresponds 
to a perfect classification and an AUC of 0.5 (the diagonal line, Figure 3) is what can 
be expected from random guessing [86,87]. As exemplified in Figure 3, the red model 
is able to maintain a high specificity while correctly classifying a large portion of the 
positive outcomes compared to the blue model. If a specificity of 0.90 is acceptable, 
the red model yields a sensitivity of 0.86 as opposed to 0.52 for the blue model. 
2.3.2 PREDICTIVE MODELS FOR COPD EXACERBATIONS 
Several previous studies have attempted to develop models for predicting upcoming 
COPD exacerbations to facilitate an early and preventive treatment [88–94]. These 
studies are based on telemonitored data from physiological measurements and/or 
respiratory symptom questionnaires (Table 2). 
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Study Predictor(s) Classification 
algorithm 
Performance 
Jensen 
2012 [88] 
- Oxygen saturation Linear discriminant 
classification 
Sens: 0.70 
Spec: 0.95 
NPV: 0.88 
PPV: 0.86 
AUC: 0.73 
van der 
Heijden 2013 
[89] 
- Lung function 
- Oxygen saturation 
- Respiratory symptoms  
Bayesian network Sens: 0.88 
Spec: 0.80 
Acc: 0.81 
AUC: 0.87 
Fernandez-
Granero 2014 
[90] 
- Respiratory symptoms  Probabilistic neural 
network 
Sens: 0.81 
Spec: 0.94 
Acc: 0.88 
NPV: 0.86 
PPV: 0.92 
Mohktar  
2015 [91] 
- Blood pressure 
- Body temperature 
- Bodyweight 
- Heart rate 
- Lung function 
- Respiratory symptoms  
Classification and 
regression tree 
(CART) 
Sens: 0.61 
Spec: 0.80 
Acc: 0.72 
Sanchez-
Morillo 2015 
[92] 
- Respiratory symptoms K-means clustering Sens: 0.75 
Spec: 0.90 
Acc: 0.85 
NPV: 0.88 
PPV: 0.79 
AUC: 0.84 
Riis  
2016 [93] 
- Blood pressure 
- Heart rate 
- Oxygen saturation 
 
 
K-nearest 
neighbour 
Sens: 0.73 
Spec: 0.74 
Acc: 0.74 
NPV: 0.78  
PPV: 0.69 
Shah  
2017 [94] 
- Heart rate 
- Oxygen saturation 
- Respiratory rate 
Logistic regression Sens: 0.60-0.80 
Spec: 0.68-0.36 
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Table 2. Previously reported predictive models for COPD exacerbations based on 
data collected through telemonitoring. Abbreviations: Sens: sensitivity, Spec: 
specificity, Acc: accuracy, NPV: negative predictive value, PPV: positive predictive 
value, AUC: area under the curve. 
Maintaining a high specificity is crucial, as the annual rate of exacerbations has been 
reported to be 2.4 to 2.7 exacerbations per patient per year in patients with moderate 
to severe COPD [40,45]. This results in a natural imbalance between outcomes when 
predicting an upcoming exacerbation. The studies by Jensen et al. [88], Fernandez-
Granero et al. [90], and Sanchez-Morillo et al. [92] all reported good performances 
with specificities in the range of 0.90 to 0.95 with corresponding sensitivities in the 
range of 0.70 to 0.81 using a linear discriminant classification algorithm, a 
probabilistic neural network, and a k-means clustering algorithm, respectively.   
However, as also concluded in a recent systematic review, predictive models have yet 
to achieve clinically useful levels of sensitivity, specificity, and accuracy [83]. 
Furthermore, it is challenging to compare the results of previously reported predictive 
models as different methods used for assessing the performance can highly influence 
the generalizability of the results. This calls for a new approach in developing 
predictive models before they can be successfully implemented in telemonitoring of 
patients with COPD. 
2.3.3 UNEXPLORED POTENTIALS 
Recently reported evidence has indicated that previous exacerbations are associated 
with an increased risk of future exacerbations [95,96]. This potential has yet to be 
investigated, as no previous studies, to our knowledge, have included information of 
previous exacerbations as a predictor. It is also well established that COPD exhibits 
seasonal variation and that environmental factors increase the risk of COPD 
exacerbation [97–100]. One might therefore further hypothesize that the frequency of 
COPD exacerbations among patients in general is potentially associated with an 
increased risk of exacerbation for the individual patient. This has also yet to be 
included in the prediction of exacerbations in patients with COPD. 
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CHAPTER 3. THESIS OBJECTIVE 
This chapter presents the overall objective of the thesis and the specific objectives 
addressed in the four thesis studies. 
COPD is a major socio-economic burden that is associated with significant morbidity 
and mortality worldwide. The impacts of COPD are mainly attributable to 
exacerbations, which are important to treat early and prevent subsequently. A 
substantial portion of unreported exacerbations is a challenge in the management of 
COPD. Telemonitoring and the application of predictive analytics have been 
suggested as a potential solution, but predictive models have yet to obtain a level of 
clinical relevance. There is unexplored potential in including information on previous 
exacerbations, both within and between patients with COPD, which could potentially 
improve the prediction of COPD exacerbations. This leads to the following objective: 
The objective of this thesis was to improve methods for assessing predictive models 
and to explore the potential of including information on previous exacerbations in 
the prediction of upcoming exacerbations in patients with COPD. 
Two data sets were obtained to form the basis for developing predictive models to 
address the thesis objective (Table 3). Data set A contained a large cohort of 
telemonitored patients with COPD from the TeleCare North Trial [101]. Data set B 
contained a small cohort with a higher frequency of measurements from a 
telemedicine project at the Department of Pulmonary Medicine, Aalborg University 
Hospital [102]. 
Table 3. Summary of the processed data sets used for developing predictive models 
for addressing the thesis objective. Exa/ctrl (exacerbation/control) periods are 
periods with or without a subsequent occurrence of exacerbation. 
Data set Patients 
included 
Variables Frequency of 
measurements 
Exa/ctrl 
periods 
A 57 - Blood pressure 
- Heart rate 
- Oxygen saturation 
- Weight 
- Respiratory symptoms 
1-2 per week 84/1652 
 
B 9 - Blood pressure 
- Heart rate 
- Oxygen saturation 
≥3 per week 17/398 
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3.1 PAPER-SPECIFIC OBJECTIVES 
The thesis objective was addressed in four separate studies that were presented in four 
papers. The specific aims of the studies are presented in Table 4. 
Study Objective Data set 
I To explore whether the patient and population incidence of 
exacerbation in a large cohort of patients with COPD contain 
predictive information of upcoming exacerbations. 
Paper I: Population exacerbation incidence contains 
predictive information of acute exacerbations in patients with 
chronic obstructive pulmonary disease in telecare 
A 
II To propose a proper validation method for developing 
predictive models, as overfitting is a prevalent problem in 
small and imbalanced data sets.  
Paper II: Double cross-validation with feature selection: An 
overfit-resistant and transparent validation method in a small 
imbalanced data set for predicting exacerbations in patients 
with COPD 
B 
III To provide a systematic comparison of classification 
algorithms for predicting COPD exacerbations in order to 
assess the sensitivity of the choice of classification algorithm. 
Paper III: A systematic approach to sensitivity-analysis of 
choice of classification algorithm for prediction of COPD 
exacerbations 
B 
IV To explore whether the inclusion of previous model-estimated 
probabilities of exacerbation can improve the prediction of 
upcoming COPD exacerbations (as a proxy for the patient and 
population incidence of exacerbation). 
Paper IV: A two-layer probabilistic model shows promising 
results for predicting COPD exacerbations for patients in 
telemonitoring 
B 
 
Table 4. The four studies and their specific objectives to address the thesis objective. 
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CHAPTER 4. SUMMARY OF PAPERS 
This chapter provides a summary of each of the four papers that have been included 
in the thesis. 
4.1 PAPER I 
Title: Population exacerbation incidence contains predictive information of 
acute exacerbations in patients with chronic obstructive pulmonary disease in 
telecare 
Introduction: No previous studies have reported predictive models that include 
information on previous exacerbations in the prediction of upcoming exacerbations. 
The objective of this study was to investigate whether the patient and population 
incidence of exacerbation contain predictive information of acute COPD 
exacerbations in combination with physiological measurements and symptom 
questionnaires. 
Methods: Weekly submissions of blood pressure, oxygen saturation, heart rate, 
weight, and a respiratory symptom questionnaire were obtained from 578 patients 
with COPD, who constituted the intervention group out of 1225 patients who were 
included in the TeleCare North Trial. The data were structured into 30-day periods 
and labelled either as an exacerbation period if the patient was hospitalized shortly 
after the period or a control period if no hospitalization occurred. Periods required at 
least three measurements during the 30 days and were otherwise excluded. Twenty-
nine predictors were extracted for every period and involved mathematical extractions 
of the physiological parameters, a symptom-defined exacerbation based on the 
questionnaire, patient incidence of exacerbation in the last three, six, and twelve 
months, and population incidence of exacerbation within the last month. Two 
predictive models were then developed based on logistic regression to differentiate 
between exacerbation periods and control periods. One model was provided with 
potential predictors from the patient and population incidence of exacerbation, while 
the other model was not. An exhaustive predictor search was used in each of the 
models to identify up to four of the most informative predictors based on five-fold 
cross-validation. Each model was evaluated by AUC using two-fold cross-validation, 
and the models were compared to assess whether the inclusion of the patient or 
population incidence of exacerbation improved the prediction of acute COPD 
exacerbations. 
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Results: A total of 84 exacerbation periods and 1652 control periods among 57 
patients were extracted from the data set. The model without the patient and 
population incidence of exacerbation was based on oxygen saturation, weight, and 
symptom-defined exacerbation and yielded a mean AUC of 0.63. In comparison, the 
model with the patient and population incidence of exacerbation as potential 
predictors was based on oxygen saturation, weight, and population incidence of 
exacerbation and resulted in a mean AUC of 0.74. The difference in AUC was 
statistically significant (p < 0.05), and the latter model obtained a sensitivity of 0.67 
at a specificity of 0.70. 
Conclusion: Population exacerbation incidence was considered an informative 
predictor for acute COPD exacerbations. The population exacerbation incidence, in 
combination with physiological parameters, increased the performance of a predictive 
model compared with a conventional model based on only physiological parameters 
and respiratory symptom questionnaires. 
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4.2 PAPER II 
Title: Double cross-validation with feature selection: An overfit-resistant and 
transparent validation method in a small imbalanced data set for predicting 
exacerbations in patients with COPD 
Introduction: Over-fitting is a prevalent problem when validating the performance 
of predictive models, especially in small imbalanced data sets. The objective of this 
study was to compare models based on double cross-validation with feature selection 
to models based on conventional cross-validation and simple validation (over-fitting). 
Methods: Daily to weekly measurements of blood pressure, oxygen saturation, and 
heart rate were obtained from 108 patients with COPD included in a telemedicine 
study at the Department of Pulmonary Medicine, Aalborg University Hospital. The 
measurements were structured into 14-day periods with a minimum of three 
measurements in both the first and the second week. If an exacerbation, defined as a 
patient-initiated self-medication plan or a hospitalization, occurred within three days 
of the last measurement, the period was defined as an exacerbation period and 
otherwise as a control period. Patients with no exacerbation periods were excluded. 
Seventy potential predictors were obtained based on mathematical extractions of 
measurements. Predictive models for COPD exacerbations were allowed up to three 
predictors and were developed based on four different classification algorithms: 
logistic regression, naive Bayes, random forest, and support vector machine. For each 
of the four classification algorithms, the models were validated based on simple 
validation, cross-validation, and double cross-validation with feature selection. The 
three validation methods were compared by ROC curves and AUC. 
Results: Nine patients remained after structuring the data set, resulting in a total of 
17 exacerbation periods and 398 control periods. By visual inspection of the ROC 
curves, the performance of the models based on cross-validation were between that of 
the models based on simple validation and double cross-validation with feature 
selection for all four classification algorithms. This was also reflected in the AUC 
values (Table 5). 
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Classification algorithm SV CV DCVFS 
Logistic regression 0.89 0.86 0.81 
Naive Bayes 0.91 0.85 0.72 
Support vector machine 0.89 0.85 0.72 
Random forest 1.00 0.88 0.78 
 
Table 5. AUC values for the models based on simple validation (SV), cross-validation 
(CV), and double cross-validation with feature selection (DCVFS) among the four 
classification algorithms. 
Conclusion: Double cross-validation with feature selection was considered a more 
robust validation method than conventional cross-validation when predicting COPD 
exacerbations in a small imbalanced data set. 
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4.3 PAPER III 
Title: A systematic approach to sensitivity-analysis of choice of classification 
algorithm for prediction of COPD exacerbations 
Introduction: A comparison of predictive models reported in previous studies is 
problematic due to varying data sets, different validation methods, and different 
classification algorithms being applied. No previous studies have reported a 
systematic comparison of classification algorithms using the same data set and the 
same validation method. The objective of this study was to systematically compare 
classification algorithms to assess the sensitivity to the choice of classification 
algorithm for predictive models for COPD exacerbations. 
Methods: Data from 108 patients with COPD were obtained from a telemedicine 
study at the Department of Pulmonary Medicine, Aalborg University Hospital. 
Patients continuously submitted home measurements of blood pressure, oxygen 
saturation, and heart rate, which were retrospectively structured into 14-day periods. 
Periods required at least three measurements in both the first and second week. 
Exacerbations were defined as a patient-initiated self-medication plan or a 
hospitalization. The periods further required no more than three days between the last 
measurement in the period and the occurrence of an exacerbation. Control periods 
were defined as periods with no subsequent exacerbation. Patients with no 
exacerbation periods were excluded from the study. Mathematical extractions of 
measurements resulted in a total of seventy-five potential predictors. Nine 
classification algorithms were included in the sensitivity analysis: linear discriminant 
classification, logistic regression, classification tree, random forest, support vector 
machine with both a linear kernel and a radial basis function kernel, naive Bayes, and 
k-nearest neighbour with both three and five nearest neighbours. A predictive model 
was developed for each classification algorithm with three predictors based on double 
cross-validation with feature selection. The predictive models were evaluated and 
compared by AUC and by sensitivity at a fixed specificity of 0.95. 
Results: A total of nine patients with 17 exacerbation periods and 398 control periods 
remained after data structuring. The comparison of the predictive models revealed that 
the different classification algorithms resulted in AUC values ranging from 0.52 to 
0.81 with a mean value of 0.71±0.10. The sensitivity at a fixed specificity of 0.95 
ranged from 0.18 to 0.65 with a mean value of 0.37±0.18. 
Conclusion: Prediction models for COPD exacerbations are highly sensitive to the 
choice of classification algorithm. Several classification algorithms should therefore 
be compared systematically when developing predictive models.   
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4.4 PAPER IV 
Title: A two-layer probabilistic model shows promising results for predicting 
COPD exacerbations for patients in telemonitoring 
Introduction: Population exacerbation incidence was previously shown to be a 
predictor of upcoming exacerbations in patients with COPD. However, this study was 
limited by the frequency of measurements and by that it is rarely possible to obtain 
continuous access to medical records to determine the day to day population 
exacerbation incidence. As an alternative to accessing medical records, this study 
attempted to use previous model-estimated probabilities of exacerbations as a proxy 
for the patient and population incidence of exacerbation. The objective of this study 
was to investigate whether a two-layer probabilistic model can increase classification 
rates compared to a conventional one-layer model for predicting COPD exacerbations. 
Methods: Continuous measurements of blood pressure, oxygen, saturation, and heart 
rate were obtained from a telemedicine study performed at the Department of 
Pulmonary Medicine, Aalborg University Hospital, which included 108 patients with 
COPD. The measurements were retrospectively structured into 14-day periods 
requiring at least three measurements in each of the weeks in the period. Exacerbation 
periods were defined as a patient-initiated self-medication plan or a hospitalization 
occurring within three days after the last measurement in the period. Control periods 
were defined as periods with no subsequently occurring exacerbations. Patients with 
no exacerbation periods were excluded from the study. Taking inspiration from 
previous work, nine classification algorithms were included in a comparison between 
a two-layer probabilistic model and a conventional one-layer model. The 
classification algorithms included were linear discriminant classification, logistic 
regression, classification tree, random forest, support vector machine with both a 
linear kernel and a radial basis function kernel, naive Bayes, and k-nearest neighbour 
with both three and five nearest neighbours. The one-layer models were based on three 
out of seventy-five potential predictors from the mathematical extractions of 
measurements and were developed based on double cross-validation with feature 
selection. The estimated probabilities of exacerbation from each one-layer model were 
used to extract eleven potential predictors in the two-layer model, which also allowed 
three predictors and was developed using double cross-validation with feature 
selection. The two models were compared by AUC and sensitivity at a fixed 
specificity of 0.95 for each classification algorithm. 
Results: Nine patients remained after structuring the data set, resulting in a total of 
17 exacerbation periods and 398 control periods. For all classification algorithms, the 
two-layer model increased the AUC value and by a mean of 0.11. The sensitivity was 
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also increased in four out of nine cases, decreased in two cases, and was unchanged 
in the remaining three cases. However, the sensitivity was increased overall by a mean 
of 0.13. The best one-layer model exhibited a sensitivity of 0.65 at a specificity of 
0.95 based on the linear discriminant classification algorithm, and the best two-layer 
model yielded a sensitivity of 0.94 at a specificity of 0.95 based on the support vector 
machine algorithm with a radial basis function kernel. 
Conclusion: A two-layer probabilistic model can significantly increase the 
classification rates to a level of clinical relevance compared to a conventional one-
layer model for predicting COPD exacerbations.
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CHAPTER 5. THESIS PAPERS 
This chapter presents the four papers that have been included in the thesis. The full 
papers are included in the appendix of the full version of the thesis. 
5.1 PAPER I 
    
Population exacerbation incidence contains predictive information of 
acute exacerbations in patients with chronic obstructive pulmonary 
disease in telecare 
Thomas Kronborg, Lasse Mark, Simon L. Cichosz, Pernille Heyckendorff Secher, 
Ole Hejlesen 
 
Published in: International Journal of Medical Informatics (2019) 
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5.2 PAPER II 
 
Double cross-validation with feature selection: An overfit-resistant and 
transparent validation method in a small imbalanced data set for 
predicting exacerbations in patients with COPD 
Thomas Kronborg, Simon L. Cichosz, Ole Hejlesen 
 
Submitted to: Computers in Biology and Medicine (2019) 
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5.3 PAPER III 
 
A systematic approach to sensitivity-analysis of choice of classification 
algorithm for prediction of COPD exacerbations 
Thomas Kronborg, Simon L. Cichosz, Ole Hejlesen 
 
Submitted to: Computers in Biology and Medicine (2019) 
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5.4 PAPER IV 
 
A two-layer probabilistic model shows promising results for predicting 
COPD exacerbations for patients in telemonitoring 
Thomas Kronborg, Simon L. Cichosz, Ole Hejlesen 
 
Submitted to: International Journal of Medical Informatics (2019) 
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CHAPTER 6. DISCUSSION 
This chapter will initially summarize the main findings and discuss the 
methodological considerations of the four papers included in the thesis. It will then 
focus on the significant insights that the thesis has provided and the future 
perspectives. 
6.1 SUMMARY OF THE MAIN FINDINGS 
The objective of this PhD study was to improve methods for assessing predictive 
models and to explore the potential of including information on previous 
exacerbations in the prediction of upcoming exacerbations in patients with COPD. 
Paper I presented how the population exacerbation incidence is an informative 
predictor for COPD exacerbations in combination with physiological parameters. 
Paper II encouraged the use of double cross-validation with feature selection, as this 
validation method was considered more robust than conventional cross-validation for 
predicting exacerbations in a small imbalanced data set. Paper III showed that 
prediction models for COPD exacerbations are highly sensitive to the choice of 
classification algorithm and that several classification algorithms should therefore be 
compared when developing predictive models. Papers IV demonstrated how previous 
model-estimated probabilities of exacerbation can be implemented in a two-layer 
probabilistic model to significantly increase classification rates for COPD 
exacerbations compared to a conventional model. 
6.2 METHODOLOGICAL CONSIDERATIONS 
The strengths of the study presented in Paper I were a relatively large sample of 
patients with COPD and that exacerbations were defined from hospitalizations. The 
sample size (n=57) increased the generalizability of the results, and a hospitalization-
defined exacerbation ensured that the models were focused on predicting only severe 
exacerbations, which cannot be managed outside of hospital [3]. These cases are also 
associated with the largest negative impact on disease progression and substantial 
healthcare costs [103]. An additional strength of the study was that two predictors 
were shared among the models with and without patient and population exacerbation 
incidence as potential predictors. This supports the fact that population exacerbation 
incidence is an informative predictor of COPD exacerbations and led to a significant 
increase in AUC. The weaknesses of the study presented in Paper I primarily included 
a low frequency of measurements and a time span of up to a week between the last 
measurement and the occurrence of exacerbation. This resulted in data structuring, 
PREDICTING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
52 
where periods only required three measurements in a 30-day period, while some 
patients measured two times a week. This presumably induced a large variance within 
the predictors, as some periods were based on three measurements, while other 
periods were based on up to eight or nine. The time span of up to a week could also 
have complicated the prediction, as the most informative predictors for predicting 
exacerbations may differ between one day and seven days prior to onset. These 
weaknesses could have caused the low performance of the models compared to other 
studies that used a higher frequency of measurements. Ideally, the frequency of 
measurements would have been increased and standardized, which would have 
provided better conditions for developing a prediction model. 
Common strengths of the studies presented in Papers II-IV included a high frequency 
of measurements and no more than three days between the last measurement and the 
occurrence of an exacerbation. This allowed a minimum of six measurements within 
a 14-day period and therefore more information closer to the occurrence of the 
exacerbation, as opposed to the study presented in Paper I. Similarly, a common 
weakness of the studies was the limited sample size (n=9), which potentially yielded 
results with a low generalizability and prevented the inclusion of more sophisticated 
algorithms that require large training sets. To address this weakness, models were 
developed and validated using double cross-validation with feature selection, and the 
results were based on several classification algorithms, as proposed in Papers II and 
III. 
The additional strength of the study presented in Paper II was that the results showed 
the same tendency with all four models based on different classification algorithms. 
The primary weakness of this study was that there was no independent test set. An 
independent test set could have provided insights into the degree of generalizability, 
where potential over-fitting of the different validation methods would have been 
reflected in a lower performance on the independent test set. 
Additional strengths of the study presented in Paper III were that several classification 
algorithms were systematically compared using the same data set and the same 
validation method. The classification algorithms were the only variable, which 
resulted in a fair comparison as opposed to comparing models from previous studies 
with different data sets, validation methods, and classification algorithms. A weakness 
of this study was, presumably, that not all classification algorithms were developed to 
their full potential, as only cost-sensitive learning was used. Several of the 
classification algorithms can be fine-tuned in many ways, but this was considered too 
comprehensive to include in the study. 
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The strength of the study presented in Paper IV was that the probabilistic two-layer 
model increased the classification rates across all the classification algorithms by a 
substantial margin. A weakness of the study was the potential of selecting different 
predictors when developing models based on double cross-validation with feature 
selection. This prevented the possibility of providing a general predictive model, 
which could be implemented in the telemonitoring of patients with COPD. However, 
the sample size was not considered sufficient for providing a general model. 
In the presented studies, exacerbations were defined from either a patient-initiated 
self-medication plan and/or a hospitalization. Prior to severe exacerbation, the 
predictors presumably vary more from the patient’s stable state compared to mild or 
moderate exacerbations, but this is uncertain. Ideally, exacerbations should have been 
stratified by severity, according to the required treatment [3], and further by length of 
stay or healthcare costs for severe exacerbations. It remains uncertain whether 
defining exacerbations from a patient-initiated self-medication plan is accurate, as 
patients with COPD have been reported to have a poor understanding of their disease 
and symptoms [40]. Patients with a good understanding of their disease and symptoms 
may be able to reduce the impact of a potential moderate or severe exacerbation 
through early recognition. In contrast, an unreported, and therefore untreated, mild or 
moderate exacerbation might have a substantial impact in patients with a poor 
understanding [104]. In this case, a two-layer probabilistic model may be a better 
alternative for defining exacerbations based on the variations from the patient’s stable 
state. This encourages research towards a model-based data-driven definition for mild 
and moderate exacerbations in combination with the hospitalization-based definition 
for severe exacerbations. 
6.3 SIGNIFICANCE OF RESEARCH 
It is challenging to compare the results of the studies included in this thesis to those 
of previously reported models for COPD exacerbations due to varying data sets and 
class imbalances, the use of different classification algorithms and different validation 
methods, and variations in the window for predicting an exacerbation. However, Shah 
et al. [94] reported a predictive model with a mediocre performance, a sensitivity of 
0.60 at a specificity of 0.68, based on logistic regression. The studies reported by Riis 
et al. [93] and Mohktar et al. [91] resulted in models having slightly better 
performances, with a sensitivity of 0.73 at a specificity of 0.74 based on the k-nearest 
neighbour algorithm and a sensitivity of 0.61 at a specificity of 0.80 based on the 
CART algorithm. Although the study by van der Heijden et al. [89] reported a good 
sensitivity of 0.88, based on a Bayesian network, a specificity of 0.80 would still cause 
a crippling amount of false positives in a telemonitoring setting given the natural 
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imbalance between periods with and without exacerbation. The models reported in 
the studies by Sanchez-Morillo et al. [92], Jensen et al. [88], and Fernandez-Granero 
et al. [90] all managed to obtain a moderate to a good sensitivity while maintaining a 
specificity of 0.90 or more. Sanchez-Morillo et al. [92] reported a sensitivity of 0.75 
at a specificity of 0.90 based on the k-means clustering algorithm, and Jensen et al. 
[88] reported a sensitivity of 0.70 at a specificity of 0.95 based on the linear 
discriminant classification algorithm. The previously reported model with the best 
performance was described in the study by Fernandez-Granero et al. [90]. This model 
demonstrated a sensitivity of 0.81 at a specificity of 0.94 based on a probabilistic 
neural network. 
Compared to previous work in the field, the model reported in Paper I resulted in a 
mediocre performance with a sensitivity of 0.67 at a specificity of 0.70 based on 
logistic regression. This was considered reasonable due to the discussed weaknesses 
of the study and as the study was focused on investigating whether the patient and 
population incidence of exacerbation contain predictive information for upcoming 
exacerbations. From the results reported in Paper IV, the best one-layer model 
exhibited a sensitivity of 0.65 at a specificity of 0.95 based on the linear discriminant 
classification algorithm, which was better or comparable to most previously reported 
models. The best two-layer model yielded a sensitivity of 0.94 at a specificity of 0.95 
based on the support vector machine algorithm with a radial basis function kernel. 
The performance of this model was superior to that of previously reported models for 
predicting COPD exacerbations. 
This thesis has presented results that have the potential to improve the state-of-the-art 
in the use of predictive analytics for managing COPD. Including information on 
previous exacerbations for predicting upcoming exacerbations resulted in a mean 
increase in the AUC of 0.12 for the prediction models presented in Paper I and a mean 
increase in the AUC of 0.11 for the prediction models presented in Paper IV. 
Comparing the two studies, a higher frequency of measurements generally resulted in 
predictive models with higher classification rates without including information on 
previous exacerbations. As presented in Paper I, the population exacerbation 
incidence was considered a good predictor in a large cohort with a lower frequency of 
measurements, while the patient exacerbation incidence was not included among the 
most informative predictors. In contrast, the model-estimated probability of 
exacerbation within patients was frequently selected as the most informative predictor 
in a smaller cohort with a higher frequency of measurements, while the model-
estimated probability of exacerbation in the population was selected less, as shown in 
the study presented in Paper IV. 
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The results from the study presented in Paper IV indicated that a two-layer 
probabilistic model is the best approach for predicting COPD exacerbations. 
Moreover, the model based on the linear discriminant classification algorithm resulted 
in the highest classification rates. The first layer model should provide a model-
estimated probability of exacerbation that is based on mathematical extractions from 
three or more weekly measurements of blood pressure, heart rate, and oxygen 
saturation from a two-week period. As a single peak in the model-estimated 
probability of exacerbation was not ideal, the second layer model should predict 
exacerbations based on the patient mean probability of exacerbation within the last 
week or two, the relative difference in probability of exacerbation from the patient 
median, and the population mean probability of exacerbation within the last week. 
6.4 FUTURE PERSPECTIVE 
Although the potential of including information on previous exacerbations in the 
prediction of upcoming exacerbations shows promising results, a general model for 
predicting COPD exacerbations has yet to be proposed. However, the results of this 
thesis have provided valuable insights into what should be included as predictors 
when developing a general predictive model. Proposing a general predictive model 
would require a large representative cohort with a high frequency of measurements. 
This might also reveal whether the model-estimated probability of exacerbation in the 
population could be an informative predictor in this case, similar to using the 
population exacerbation incidence presented in Paper I. 
Based on the results included in the thesis, it has been agreed that the two-layer 
probabilistic model will be deployed into and tested in an already existing 
telemonitoring platform in the North Denmark Region. This has been chosen as a 
signature project supported by the Danish government, Local Government Denmark, 
and the Danish Regions as a part of a new national strategy to use artificial intelligence 
for improving healthcare [105]. A large cohort of patients with COPD will be 
instructed to perform frequent measurements of blood pressure, heart rate, and oxygen 
saturation. The study will be a cluster-randomized controlled trial in which healthcare 
personnel in the control group will manage patients with typical telemonitoring and 
those in the intervention group will manage patients assisted with a prediction model 
for exacerbations in combination with typical telemonitoring. The groups will be 
compared according to health-related quality of life, number of hospitalizations 
among the patients, and total healthcare costs to determine the true value of using 
predictive analytics for managing patients with COPD. 
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The two-layer probabilistic model approach will hopefully inspire future research in 
predictive analytics towards treating COPD as a multimodal systemic disease. Thus 
far, the prediction of COPD exacerbations has been approached by treating COPD 
solely as a respiratory disease. Using several first layer models for each of the 
comorbidities of COPD could potentially increase the generalizability of a prediction 
model to a much larger group of multimodal chronic patients. A good starting point 
would be to include a cardiovascular first layer model, as cardiovascular diseases are 
the most important comorbidities of COPD [56] and a frequent component in 
exacerbations [66]. 
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CHAPTER 7. CONCLUSION 
This chapter concludes the thesis. 
In conclusion, double cross-validation should be used to develop and compare models 
based on several classification algorithms, and there is great potential in including 
information on previous exacerbations in the prediction of upcoming exacerbations in 
patients with COPD. Although this has been clinically recognized, no previous studies 
have included this aspect in the development of predictive models. This thesis has 
presented how information on previous exacerbations can be utilized to significantly 
increase classification rates for predictive models to a level of clinical relevance. This 
encourages the implementation of a predictive model in COPD telemonitoring to 
predict exacerbations and facilitate early and preventive treatment. This could 
potentially decrease the impact of exacerbations and reduce the morbidity, mortality, 
and socio-economic burden related to COPD. 
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